scutellarein and Infarction--Middle-Cerebral-Artery

scutellarein has been researched along with Infarction--Middle-Cerebral-Artery* in 3 studies

Other Studies

3 other study(ies) available for scutellarein and Infarction--Middle-Cerebral-Artery

ArticleYear
Synthesis and bioevaluation of Scutellarein-Tertramethylpyrazine hybrid molecules for the treatment of ischemic stroke.
    Bioorganic chemistry, 2024, Volume: 142

    Ischemic stroke caused by insufficient blood supply to the brain may produce a sequence of cascade reactions, leading to oxidative stress and ultimately inducing nerve cell damage. Therefore, hybrid molecules with multiple therapeutic effects have irreplaceable advantages for the treatment of ischemic stroke. Based on the previous works, two types of Scutellarein and Tertramethylpyrazine hybrid molecules were designed and synthesized according to the PepT 1-based design. After systematic research, all synthesized hybrid molecules exhibited more excellent neuroprotective effect and antiplatelet activity compared to the original drugs. Among them, the selected compound 1e with superior neuroprotective and antiplatelet effects could significantly enhance the permeability on the Caco-2 monolayer membrane and inhibit the Gly-Sar uptake on Caco-2 cells. Meanwhile, the result of intestinal perfusion has also confirmed that the absorption of the selected compound 1e is indeed increased. Further, the selected compound 1e significantly reduce the cerebral infarction volume of middle cerebral artery occlusion/reperfusion rats. Especially, the cerebral infarction volume of the high-dose 1e group reduced to one fourth of the model group. Meanwhile, results of hematoxylin-eosin staining also indicated that the damage in the hippocampus CA1 region was significantly alleviated after treatment with the compound 1e. Accordingly, molecular hybridization strategy is one of the simple and feasible ways to improve the therapeutic effect of single targeted drug.

    Topics: Animals; Caco-2 Cells; Humans; Infarction, Middle Cerebral Artery; Ischemic Stroke; Neuroprotective Agents; Rats; Reperfusion Injury

2024
Hybrid molecules of scutellarein and tertramethylpyrazine's active metabolites for ischemic stroke.
    Bioorganic & medicinal chemistry letters, 2019, 10-01, Volume: 29, Issue:19

    Topics: Animals; Apigenin; Brain Ischemia; Disease Models, Animal; Infarction, Middle Cerebral Artery; Neurons; Neuroprotective Agents; PC12 Cells; Pyrazines; Rats; Reperfusion Injury; Stroke

2019
Synthesis and protective effect of scutellarein on focal cerebral ischemia/reperfusion in rats.
    Molecules (Basel, Switzerland), 2012, Sep-06, Volume: 17, Issue:9

    Scutellarein, the main metabolite of scutellarin in vivo, has relatively better solubility, bioavailability and bio-activity than scutellarin. However, compared with scutellarin, it is very difficult to obtain scutellarein from Nature. Therefore, the present study focused on establishing an efficient route for the synthesis of scutellarein by hydrolyzing scutellarin. Neurological deficit score and cerebral infarction volume with the administration of scutellarein were then used to compare its neuroprotective effects on focal cerebral ischemia/reperfusion in rats induced by middle cerebral artery occlusion (MCAO) with those of scutellarin. The results showed that scutellarein had better protective effect on focal cerebral ischemia/reperfusion than scutellarin, which laid the foundation for further research and development of scutellarein as a promising candidate for ischemic cerebro-vascular disease.

    Topics: Animals; Apigenin; Brain Ischemia; Glucuronates; Infarction, Middle Cerebral Artery; Neuroprotective Agents; Rats; Reperfusion Injury

2012